ProteoGenix

Executive Summary

ProteoGenix is a France-based contract research organization (CRO) and reagent supplier established in 2003, specializing in custom antibody production, protein expression, and gene synthesis. The company differentiates itself through proprietary AI tools for antibody optimization and a hybrid business model offering both custom services and a catalog of over 15,500 off-the-shelf products. Serving clients in therapeutics, diagnostics, research, and animal health, ProteoGenix has built a strong foothold in the European biotech ecosystem. With increasing demand for biologics and antibody-based therapeutics, the company is well-positioned to capitalize on the growing outsourcing trend in drug development. Its long operational history and diversified revenue streams provide stability, while adoption of AI enhances efficiency and differentiation. However, limited public disclosure and a Phase 1 stage imply early commercialization, requiring sustained investment in sales and innovation. Overall, ProteoGenix represents a promising but early-stage player in the competitive CRO space.

Upcoming Catalysts (preview)

• Q3 2026Launch of new AI-driven antibody optimization platform75% success
• Q4 2026Strategic partnership with a major pharma or biotech for custom antibody services60% success